Generex unveils positive results of Oral-lyn's Phase III trial

07/11/2011 | American City Business Journals

Two Phase III trials of Generex Biotechnology's Oral-lyn showed that the drug helped regulate blood glucose levels in patients with type 1 diabetes. The oral insulin is not linked to severe hypoglycemia, weight changes and development of insulin antibodies in patients with the disease, the company said.

View Full Article in:

American City Business Journals

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI